Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population atrial fibrillation

Journal of Clinical Pharmacology

Volumn 41, Issue 1, 2001, Pages 92-96

  Chow, Moses S S ^a   White, C Michael ^b,c   Lau, Chu Pak ^a   Fan, Chengde ^c   Tang, Man Oi ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYPROPAFENONE; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; DEXTRORPHAN; PROPAFENONE;

ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG OXIDATION; DRUG URINE LEVEL; FEMALE; HEART ATRIUM FIBRILLATION; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; STEADY STATE;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHINA; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HONG KONG; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PROPAFENONE;

EID: 0034747788     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122009737     Document Type: Article

References (21)

1. Update: Clinically significant cytochrome P-450 drug interactions
2. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota
3. Determination of dextromethorphan metabolizer phenotype in healthy volunteers
4. Dextromethorphan polymorphic hepatic oxidation (CYP 2D6) in healthy black american adult subjects
5. Low frequency of slow debrisoquine hydroxylation in a native Chinese population
6. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and s-mephenytoin
7. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects
8. Debrisoquine hydroxylation capacity: Problems of asessment in two populations
9. Pharmacoanthropology: Drug metabolism
10. Polymorphism of dextromethorphan metabolism: Relationships between phenotype, genotype and response to the administration of encainide in humans
11. Propafenone in a usual dose produces severe side-effects: The impact of genetically determined metabolic status on drug therapy
12. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences
13. Clinical pharmacology of propafenone: Pharmacokinetics, metabolism and concentration-response relations
14. Phenotypic polymorphic drug metabolism in the French Caucasian population
15. Dextromethorphan phenotypes determined by high performance liquid chromatography and fluorescence detection
16. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine
17. Identification of propafenone metaboliser phenotype from plasma and urine excretion data
18. High-performance liquid chromatographic analysis of propafenone in human plasma samples
19. Normal-phase high-performance liquid chromatographic procedure for the determination of diprofenone in plasma
20. Fluoxetine impairs the CYP2DT-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers
21. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine